Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

VIBATIV

TELAVANCIN

Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview VIBATIV is listed in Drugs@FDA under application 022407 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TELAVANCIN Form and strength INJECTABLE; INJECTION - 250MG Sponsor THERAVANCE INC Submission history Latest submission status date: 2013-06-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview VIBATIV is listed in Drugs@FDA under application 022407 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TELAVANCIN Form and strength INJECTABLE; INJECTION - 250MG Sponsor THERAVANCE INC Submission history Latest submission status date: 2013-06-21 00:00:00. Submission type: ORIG.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
VIBATIV (TELAVANCIN) | Drug Monograph | MedicHelpline